XOMA: In Pursuit Of Novel Diabetes Drugs And New Collaborators
Prohost Biotech - Friday, March 09, 2012
In chronic debilitating diseases, improved therapeutics are those state-of-the-art drugs that control the devastating symptoms and limit, or prevent disease progression without causing other pathologies through the treatments’ adverse effects.
It looks as if Xoma might have a promising new drug for diabetes that promises to fulfill the above requirements for breakthrough drugs.
In the news, XOMA (XOMA) has used its technological monoclonal capability to correct hyperglycemia in a mouse model of diabetes with a first in kind long-acting XMetA fully-human allosteric monoclonal antibody to the insulin receptor. The study is published in the May issue of the American Diabetes Association's journal Diabetes. Results of a study conducted by XOMA and confirmed by investigators at the University of California, San Francisco demonstrate that XMetA has potential to control blood glucose levels in patients with diabetes.